Cardiometabolic criteria as predictors and treatment targets of liver‐related events and cardiovascular events in metabolic dysfunction‐associated steatotic liver disease

The diagnosis of metabolic dysfunction-associated steatotic liver disease (MASLD) requires at least one of five cardiometabolic criteria. It is unclear whether these criteria can be used as predictors and treatment targets for complications including liver-related events and major adverse cardiovascular events (MACE).